Glenmede Trust Co. NA Grows Stock Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Glenmede Trust Co. NA lifted its position in Henry Schein, Inc. (NASDAQ:HSIC) by 13.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,257 shares of the company’s stock after buying an additional 1,324 shares during the quarter. Glenmede Trust Co. NA’s holdings in Henry Schein were worth $821,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of HSIC. Cromwell Holdings LLC increased its stake in Henry Schein by 93.4% during the third quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock worth $26,000 after purchasing an additional 170 shares during the period. Studio Investment Management LLC grew its holdings in shares of Henry Schein by 3.8% in the third quarter. Studio Investment Management LLC now owns 4,674 shares of the company’s stock valued at $341,000 after purchasing an additional 172 shares in the last quarter. Simplify Asset Management Inc. increased its stake in Henry Schein by 5.0% during the 2nd quarter. Simplify Asset Management Inc. now owns 3,695 shares of the company’s stock worth $237,000 after buying an additional 175 shares during the period. Sequoia Financial Advisors LLC lifted its holdings in Henry Schein by 3.2% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 5,680 shares of the company’s stock worth $364,000 after buying an additional 176 shares in the last quarter. Finally, Mather Group LLC. boosted its position in Henry Schein by 16.8% in the 2nd quarter. Mather Group LLC. now owns 1,502 shares of the company’s stock valued at $96,000 after buying an additional 216 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Activity

In other news, COO Michael S. Ettinger sold 12,240 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the sale, the chief operating officer now directly owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. This represents a 12.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the transaction, the senior vice president now directly owns 71,833 shares in the company, valued at approximately $4,978,026.90. This represents a 22.65 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on HSIC. Robert W. Baird reduced their price objective on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Barrington Research reiterated an “outperform” rating and issued a $82.00 price objective on shares of Henry Schein in a research note on Wednesday, November 6th. StockNews.com upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. decreased their price target on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Finally, UBS Group lowered their price target on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Six investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $79.38.

Henry Schein Trading Down 0.7 %

Shares of Henry Schein stock opened at $76.50 on Tuesday. Henry Schein, Inc. has a 12-month low of $63.67 and a 12-month high of $82.63. The stock has a market cap of $9.54 billion, a price-to-earnings ratio of 31.48, a PEG ratio of 2.21 and a beta of 0.87. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The company has a fifty day simple moving average of $71.57 and a 200-day simple moving average of $69.88.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business’s revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.32 earnings per share. On average, equities analysts forecast that Henry Schein, Inc. will post 4.78 EPS for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.